The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers
Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban). We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity in response to smoking...
Brief Summary
Official Title: “The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.”
Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban). We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity in response to smoking and neutral cues in Positron Emission Tomography using FDG.
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
- Study Primary Completion Date: October 2007
Detailed Clinical Trial Description
Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.
Intervention(s) in this Clinical Trial
- Drug: Bupropion (Zyban)
- 1 tablet a day increasing to 2 tablets a day after a week
Outcome Measures for this Clinical Trial
Primary Measures
- Brain metabolic activity (FDG) in response to craving and neutral cues.
- Time Frame: 30-40 minutes
Safety Issue?: No
- Time Frame: 30-40 minutes
Secondary Measures
- Subjective ratings of craving
- Time Frame: 10 minutes
Safety Issue?: No
- Time Frame: 10 minutes
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Cigarette smokers (over 1 pack a day)
- Age 20-65, male-females
Exclusion Criteria:
- Dependence on other substances
- Psychiatric diagnosis
- Neurological disorder
- Obesity
- Young persons
- Pregnant women
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 65 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: Tel-Aviv Sourasky Medical Center Other
Overall Clinical Trial Officials and Contacts
Einat Even-Sapir, M.D, Ph.D Principal Investigator Tel-Aviv Sourasky Medical Center
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00267813
Study ID Number: TASMC-O5-EE-065-CTIL
ClinicalTrials.gov Identifier: NCT00267813
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00267813
